A number of firms have modified their ratings and price targets on shares of Enovis (NYSE: ENOV) recently:
- 7/21/2026 – Enovis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 7/8/2026 – Enovis is now covered by BMO Capital Markets. They set an “outperform” rating and a $29.00 price target on the stock.
- 7/8/2026 – Enovis had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 7/8/2026 – Enovis was upgraded by BMO Capital Markets to “strong-buy”.
- 7/6/2026 – Enovis was given a new $32.00 price target by Evercore Inc.
- 7/6/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
- 6/30/2026 – Enovis was downgraded by Zacks Research from “hold” to “strong sell”.
- 6/28/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
- 6/20/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
- 6/6/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
- 6/1/2026 – Enovis was downgraded by Zacks Research from “strong-buy” to “hold”.
Insider Buying and Selling at Enovis
In related news, insider Oliver Engert acquired 1,200 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders bought 4,200 shares of company stock worth $92,084. Insiders own 2.90% of the company’s stock.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
See Also
- Five stocks we like better than Enovis
- Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough
- TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power
- Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off?
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
Receive News & Ratings for Enovis Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
